Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL25267224 | 1.00 | CA4 (0.61) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL21807340 | 0.98 | CA4 (0.65) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL21807344 | 0.98 | CA4 (0.65) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL30809599 | 0.94 | CA4 (0.59) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL10438269 | 0.91 | LMNA (0.65) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL17965941 | 0.90 | LMNA (0.62) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL8160075 | 0.90 | LMNA (0.62) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Citric Acid SCHEMBL8731625 | 0.90 | LMNA (0.62) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Gluconic Acid SCHEMBL20906377 | 0.90 | LMNA (0.62) | CA4LMNAL3MBTL1TDP1PDE4A | |
| Gluconic Acid SCHEMBL28813672 | 0.90 | LMNA (0.62) | CA4LMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047021-A1 | COMPOSITIONS PROVIDING PARENTERAL NUTRITION AND TRACE ELEMENTS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2026-03-05 | — | — | WO | claimed |
| US-12629345-B2 | Methods, compositions, and devices for drug / live cell microarrays | PATHAK HOLDINGS LLC (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130844-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | AMERICAN REGENT, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026047021-A1 | COMPOSITIONS PROVIDING PARENTERAL NUTRITION AND TRACE ELEMENTS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2026-03-05 | — | — | WO | disclosed |
| US-20250241941-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | VIFOR (INTERNATIONAL) AG (SWITZERLAND) (CH) | 2025-07-31 | — | — | US | disclosed |
| US-12239657-B2 | Iron compositions and methods of making and using them | VIFOR (INTERNATIONAL) AG (CH) | 2025-03-04 | — | — | US | disclosed |
| CN-116636620-B | Black egg white peptide composition and application thereof | 南昌大学 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024263116-A1 | A STABLE CAPSULE COMPOSITION WITH GASTRO-RESISTANT PELLETS FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA | ILKO ILAC SANAYI VE TICARET A.S. (TR) | 2024-12-26 | — | — | WO | disclosed |
| US-20240252452-A1 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS | PATHAK HOLDINGS LLC | 2024-08-01 | — | — | US | disclosed |
| US-11969398-B2 | Methods, compositions, and devices for making sustained biodegradable implants in tissue | PATHAK HOLDINGS LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20040023334-A1 | Modified transferrin fusion proteins | BIOREXIS PHARMACEUTICAL CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1372728-A1 | COMPOSITIONS COMPRISING AN O/W EMULSION CONTAINING CONJUGATED LINOLEIC ACID | Natural ASA (NO) | 2004-01-02 | — | — | EP | disclosed |
| US-20030226155-A1 | Modified transferrin-antibody fusion proteins | BIOREXIS PHARMACEUTICAL CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030221201-A1 | Modified transferrin fusion proteins | BIOREXIS PHARMACEUTICAL CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1363951-A2 | POLYNUCLEAR COMPLEX FE(III) WITH PULLULAN OLIGOMERS, PROCESS OF ITS OBTAINING, AND PHARMACEUTICAL PREPARATIONS ON THE BASIS OF THE COMPLEX | AD "Zdravlje" Farmaceutsko - Hemijska Industrija, Centar Za Istrzivanje I Razvoj (YU) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003020746-A1 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002070014-A1 | COMPOSITIONS COMPRISING AN O/W EMULSION CONTAINING CONJUGATED LINOLEIC ACID | NATURAL ASA (NO) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002046241-A2 | POLYNUCLEAR COMPLEX FE(III) WITH PULLULAN OLIGOMERS, PROCESS OF ITS OBTAINING, AND PHARMACEUTICAL PREPARATIONS ON THE BASIS OF THE COMPLEX | AD 'ZDRAVLJE' FARMACEUTSKO - HEMIJSKA INDUSTRIJA, CENTAR ZA ISTRAZIVANJE I RAZVOJ (YU) | 2002-06-13 | — | — | WO | disclosed |
| US-20020049161-A1 | Pharmaceutical combination preparations containing erythropoietin and iron preparations | ROCHE DIAGNOSTICS GMBH | 2002-04-25 | — | — | US | disclosed |
| US-6333306-B1 | ADMINISTERING ERYTHROPOIETIN AND A PHYSIOLOGICALLY TOLERABLE IRON PREPARATION FOR THERAPY OF ANEMIA IN HEMODIALYSIS PATIENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629345-B2 | Methods, compositions, and devices for drug / live cell microarrays | SRMS, FKBP4, MYL4 | CA4 2362/4885LMNA 2313/4885L3MBTL1 2503/4885 |
| US-20260130844-A1 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | SLC40A1, FECH, HAMP | CA4 255/4885LMNA 3666/4885L3MBTL1 1208/4885 |
| US-20030221201-A1 | Modified transferrin fusion proteins | TFRC, FTH1, F13B | CA4 2357/4885LMNA 3890/4885L3MBTL1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.